Guggenheim Initiates Coverage On Prime Medicine with Buy Rating, Announces Price Target of $24
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Debjit Chattopadhyay has initiated coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and a price target of $24.
July 31, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Prime Medicine has been initiated with a Buy rating by Guggenheim, with a price target of $24.
The initiation of coverage by Guggenheim with a Buy rating indicates a positive outlook for Prime Medicine. The price target of $24 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100